Improved deal signals NICE recommendation of sickle cell treatment voxelotor
Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE in final draft guidance.
-
Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatment
Dabrafenib with trametinib is a targeted treatment that can be taken at home rather than hospital and improves the length and quality of life for patients.
-
170,000 people in England to have further treatment choice for preventing migraine attacks.
In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.
-
Children and young adults to benefit after NICE recommends personalised immunotherapy to treat blood cancer be made routinely available on the NHS
Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia
